Diagnostic and prognostic markers for human prostate cancer

Prostate

Volumn 31, Issue 4, 1997, Pages 264-281

  Gao, Xiang ^a   Porter, Arthur T ^a,b   Grignon, David J ^a   Pontes, J Edson ^a   Honn, Kenneth V ^a,b,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Diagnosis; Prognosis; Prostatic carcinoma; Tumor markers

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER STAGING; DIAGNOSTIC VALUE; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; TREATMENT PLANNING;

ACID PHOSPHATASE; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; GENES, P53; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030981435     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970601)31:4<264::AID-PROS8>3.0.CO;2-K     Document Type: Review

References (195)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1995. Ca 1996;65:5-27.
2. Chiarodo A: National Cancer Institute roundtable on prostate cancer: Future research directions. Cancer Res 1991;51:2498-2505.
3. Sakti D, Crawford ED (eds): "Cancer of the Prostate." New York: Marcel Dekker, 1993:1-12.
4. Garnick MB: Prostate cancer: Screening, diagnosis, and management. Ann Int Med 1993;118:804-818.
5. Sellers TA, Potter JD, Rich SS, Drinkard CR, Bostick RM, Kushi LH, Zheng W, Foison AR: Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 1994;86:1860-1865.
6. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, Teh C-Z, Paffenbarger RS Jr: Prostate Cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995;87:652-661.
7. Isaacs SD, Kiemeney LALM, Baffoe-Bonnie A, Beaty TH, Walsh PC: Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995;87:991-996.
8. Roach M, Krall J, Deller JW, Ferez CA, Sause WT, Doggett RL, Rotman M, Russ H, Pilepich MV, Asbell SO: The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols. Int J Radiat Oncol Biol Physiol 1992;24:441-449.
9. Baquet CR, Horm JW, Gibbs T, Greewnwald P: Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 1991;83:551-557.
10. Brawn PN, Johnson EH, Juhl DL, Riggs MW, Speights VO, Johnson CF, Pandya PP, Lind ML, Bell NF: Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 1993;71:2569-2563.
11. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ: Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 1993;53:2723-2727.
12. Gao X, Wu N, Grignon D, Zacharek A, Liu H, Salkowski A, Li G, Sakr W, Sarkar F, Porter AT, Chen YQ, Honn KV: High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 1994;9:2999-3003.
13. Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT, Honn KV: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 1995;11:1395-1398.
14. Gao X, Porter AT, Honn KV: Tumor suppressor genes and their involvement in human prostate cancer. Cancer Mol Biol 1995;2:475-498.
15. Gao X, Zacharek A, Grignon D, Liu H, Sakr W, Porter AT, Chen YQ, Honn KV: High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostate cancer. Intl J Oncol 1995;6:111-117.
16. Gao X, Zacharek A, Grignon DJ, Sakr W, Porter AT, Honn KV: Localization of potential tumor suppressor loci to a <2 Mb region on chromosome 17q in human prostate cancer. Oncogene 1995;11:1241-1247.
17. Gao X, Zacharek A, Salkowski A, Grignon D, Sakr W, Porter AT, Honn KV: Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995;55:1002-1005.
18. Gao X, Honn KV: Recessive oncogenes: Current status. Pathol Oncol Res 1995;1:7-22.
19. Wolff JM, Stephenson RN, Jakse G, Habib FK: Retinoblastoma and p53 genes as prognostic indicators in urological oncology. Urol Int 1994;53:1-5.
20. Bookstein R, Allred C: Recessive oncogenes. Cancer 1993;71: 1179-1186.
21. Bookstein R: Tumor suppressor genes in prostatic oncogenesis. J Cell Biochem 1994;19:S217-S223.
22. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, Ewing CM: Molecular biology of prostate cancer. Semin Oncol 1994;21:514-521.
23. Chodak GW, Thisted RA, Gerber GS, Johansson J-E, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J: Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
24. Porter AT, Kaczor JG, Forman JD: Perspectives on the role of radiotherapy and organ confined and locally advanced prostate cancer. Eur Urol 1993;24:39-43.
25. Fowler FJ, Barry MJ, Lu-Yao G: Patient reported complications in follow-up treatment after radical prostatectomy. Urol 1993; 42:622-629.
26. Gutman EB, Sproul EE, Gutman AB: Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936;28:485-495.
27. Shulman S, Mamrod L, Gonder MJ, Soanes WA: The detection of prostatic acid phosphatase by antibody reactions in gel diffusion. J Immunol 1964;93:474-480.
28. Ostrowski WS, Kucie R: Human prostatic acid-phosphatase-selected properties and practical applications. Clin Chim Acta 1994;226:121-129.
29. Sharief FS, Lee H, Leuderman MM, Lundwall A, Deaven LL, Lee CL, Li SS: Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. Biochem Biophys Res Commun 1989; 160:79-86.
30. Sharief FS, Li SSL: Structure of human prostatic phosphatase gene. Biochem Biophys Res Commun 1992;184:1468-1476.
31. Lee CT, Oesterling JE: Diagnostic markers of prostate-cancer-utility of prostate-specific antigen in diagnosis and staging. Semin Surg Oncol 1995;11:23-35.
32. Yam LT, Janckila AJ, Lam WK, Li CY: Immunohistochemistry of prostatic acid phosphatase. Prostate 1981;2:97-107.
33. Armbruster DA: Prostate-specific antigen: Biochemistry, analytical methods and clinical application. Clin Chem 1993;39: 181-195.
34. Gillatt D, Reynard JM: What is the normal range for prostate-specific antigen-use of a receiver operating characteristic curve to evaluate a serum marker? Br J Urol 1995;75:341-346.
35. Vihko P, Kontturi M, Lukkarinen O, Ervasti J, Vihko R: Screening for carcinoma of the prostate: Rectal examination, and enzymatic and radioimmunologic measurements of serum acid phosphatase compared. Cancer 1985;56:173.
36. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate-specific antigen. Invest Urol 1979;17:159-163.
37. Wang MC, Papsidero LD, Kuriyama M, Balenzuela LA, Murphy GP, Chu TM: Prostate antigen: A new potential marker for prostatic cancer. Prostate 1981;2:89-96.
38. Watt WWK, Lee P-J, M'Timkulu T, Chan W-P, Loor R: Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
39. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant serminal vesicle protein. J Clin Invest 1985;76:1899-1903.
40. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
41. Riegman PHJ, Vlietstra RJ, Van der Korpert JAGM, Romijn JC, Trapman J: Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. Biochem Biophys Res Commun 1989;159:95-102.
42. Young CY, Montgomery BY, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ: Hormonal regulation of prostate specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991;51:3748-3752.
43. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ: Hormonal regulation of prostate specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 1992;21: 63-73.
44. Henttu P, Liao S, Vihko P: Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but downregulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 1992;130:766-772.
45. Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P: Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 1994;59:129-132.
46. Guo Y, Pili R, Passaniti: Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone and extracellular matrix. Prostate 1994;24:1-10.
47. Andrews PE, Young CY-F, Montgomery BT, Tindall DJ: Tumor promoting phorbol ester down regulates the androgen induction of prostate specific antigen in a human prostatic adenocarcinoma cell line. Cancer Res 1992;52:1525-1529.
48. Sheth AR, Garde SV, Mehta MK, Shah MG: Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide. Indian J Exp Biol 1992;30:157-161.
49. Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren R III, Murphy GP: Effect of exogenous testosterone replacement on prostate specific antigen and prostate specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995;59:246-250.
50. Yu D, Dimandis EP, Sutherland DJA: Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-79.
51. Yu H, Diamandis EP, Monne M, Croce C: Moral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem 1995;270:6615-6618.
52. Breul J, Pickl U, Hartung A: Prostate specific antigen in urine and saliva. J Urol 1993;149:302A.
53. Frazier HA, Humphrey PA, Burchette JL, Paulson DF: Immunoreactive prostatic specific antigen in male periurethral glands. J Urol 1992;147:246-248.
54. Iwakiri J, Grandbois K, Wehner N, Graves HCB, Stamey T: An analysis of urinary prostatic specific antigen before and after radical prostatectomy: Evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 1993;149:783-786.
55. Kamoshida S, Tsutsumi Y: Extraprostatic localization of prostate acid phosphatase and prostate-specific antigen: Distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 1990;21:1108-1111.
56. Yu H, Diamandis EP: Prostate-specific antigen in milk of lactating women. Clin Chem 1995;41:54-58.
57. Yu H, Diamandis EP: Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 1995;153:1004-1008.
58. Papotti M, Paties C, Peveri V, Moscuzza L, Bussolati G: Immunocytochemical detection of prostate specific antigen (PSA) in skin adnexal and breast tissues and tumors. Basic Appl Histochem 1989;33:25-89.
59. Van Krieken JH: Prostate marker immunoreactivity in salivary gland neoplasms. Am J Surg Pathol 1993;17:410-414.
60. Pummer K, Wirnserger G, Purstner P, Stettner H, Wandschneider G: False positive prostate specific antigen values in the sera of women with renal cell carcinoma. 1992;J Urol 148: 21-23.
61. McLachlin CM, Srigley JR: Prostatic tissue in mature cystic teratomas of the ovary. Am J Surg Pathol 1993;16:780-784.
62. Smith MR, Biggar S, Hussain M: Prostate-specific antigen messenger RNA in expressed in nonprostate cells: Implications for detection fo micrometastases. Cancer Res 1995;55:2640-2644.
63. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P: Prostate specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995;55:2104-2110.
64. Diamandis EP, Yu H, Sutherland DJA: Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:301-310.
65. Djavan B, Keffer JH, Molberg K, Roehrborn CG: False-positive serum prostate-specific antigen values in a patient with non-Hodgkin-lymphoma of the kidney. Urology 1995;45:875-878.
66. Monne M, Croce CM, Yu H, Diamandis EP: Molecular characterization of prostate-specific antigen messenger-RNA expressed in breast-tumors. Cancer Res 1994;54:6344-6347.
67. Wu JT: Assay for prostate specific antigen (PSA): Problems and possible solutions. J Clin Lab Anal 1994;8:51-62.
68. Lankford SP, Peters KL, Elser RC: Potential effects of age-specific reference ranges for serum prostate specific antigen. Eur Urol 1995:27:182-186.
69. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147:841, 1992.
70. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD: Prostate cancer detection in a clinical urological pratice by ultrasonography, digital rectal examination, and prostate specific antigen. J Urol 143:1146, 1990.
71. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J: Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 147:846, 1992.
72. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156, 1991.
73. Wang TY, Kawaguchi TP: Preliminary evaluation of measurement of serum prostate specific antigen level in detection of prostate cancer. Ann CLin Lab Sci 16:461-466, 1986.
74. Bhatti PG, Ray P, Guinan P: An evaluation of prostate specific antigen in prostatic cancer. J Urol 137:686-689, 1987.
75. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909, 1987.
76. Brawer MK: Prostate-specific antigen: Critical issues. Urol 1994;44:9-17.
77. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostate specific antigen density: A means of distingushing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-816.
78. Mueller EJ, Coventry J, Desmond PM, Zeidman EJ, Thompson IM: Relative performance characteristics of prostate specific antigen and prostatic specific antigen density for the diagnosis of carcinoma of the prostate. Urol Oncol 1995;1:84-87.
79. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-2220.
80. Stamey T, Kabalin J, Ferrari M, Yans N: Prostate specific antigen in the diagnoses and treatment of adenocarcinoma of the prostate. IV: Anti-androgen treated patients. J Urol 1989;141: 1098-1090.
81. Akimoto S, Masai M, Akakura K, Shimazaki J: Tumor marker doubling time in patients with prostate cancer determination of prostate specific antigen and prostatic acid phosphatase doubling time. Eur Urol 1995;27:207-212.
82. Christensson A, Bjork T, Nilsson O, Dahler U, Matikainen MT, Cockett AT, Abrahamsson PA, Lilja H: Serum prostate specific antigen complexed to α1-antichymotrypsin as a indicator of prostate cancer. J Urol 1993;150:100-105.
83. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-936.
84. Wright GL Jr, Haley C, Beckett ML, Schellhanner PF: Expression of prostate specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28.
85. Rochon YP, Horoszewicz JS, Boynton AL, Holmes EH, Barren RJ III, Erickson SJ, Kenny GM, Murphy GP: Western blot assay for prostate specific membrane antigen in serum of prostate cancer patients. Prostate 1994;25:219-223.
86. Murphy G, Ragde H, Kenny G, Barren R, Erickson S III, Tjoa B, Boynton A, Holmes E, Gilbaugh J, Douglas T: Comparison of prostate specific membrane antigen, and prostate specific antigen levels in porstatic cancer patients. Anticancer Res 1995; 15:1473-1480.
87. Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, Barren RJ: Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP based enzyme linked imunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 1995;26:164-168.
88. Israeli RS, Powell CT, Fair WR, Heston WDW: Molecular cloning of a complementary DNA encoding a prostate specific membrane antigen. Cancer Res 1993;53:227-230.
89. Stamey TA, Kabalin JN: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989;141:1070-1075.
90. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW: Expression of the prostate specific membrane antigen. Cancer Res 1994;54:1807-1811.
91. Israeli RS, Miller WH Jr, Su SL, Powell T, Fair WR, Samadi DD, Huryk RF, DeBlasio A, Edwards ET, Wise GJ, Heston, WDW: Sensitive nested reverse transcription polymerase chain reactin detection of circulation prostatic tumor cells: Comparison of prostate specific membrane antigen and prostate specific antigen based assays. Cancer Res 1994;54:6306-6319.
92. Su LS, Huang I-P, Rair WR, Powell CT, Heston WDW: Alternatively spliced variants of prostate specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 1995;55:1441-1443.
93. Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Tool K, McMahon D, Benson MC, Katz AE: Molecular staging of prostate cancer. II. A comparison of the applications of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995;153:1373-1378.
94. 111indium-labeled monoclonal-antibody cyt-356. J Urol 152:1952-1955, 1994.
95. Axelrod HR, Gilman SC, D'Aleo CJ: Precliniclal results and human immunohistochemical studies with 90Y-CTY-356: A new prostatic cancer therapeutic agent. J Urol 1992;147:361A.
96. Teni TR, Sheth AR, Kamath MR, Sheth NA: Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and crarcinoma of prostate. Cancer Lett 1988;43:9-14.
97. Garde SV, Sheth AR, Venkatesan VM, Panchal CJ, Porter AT, Grignon DJ: Prostate inhibin peptide (PIP) in prostate cancer: A comparative immunohistochemical study with prostate specific antigen (PSA) and prostatic acid phosphatase (PAP). Cancer Lett 1994;78:11-17.
98. Hurkadli KS, Lokeshwar B, Sheth AR, Block NL: Detection of prostatic-inhibin-like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell-line. Prostate 1994;24: 285-290.
99. Dube JY, Pelletier G, Gagnon P, Tremblay RR: Immunohistochemical localization of a prostatic secretory protein of 94 amino acids in normal prostatic tissue, in primary prostatic tumors and in their metastases. J Urol 1987;138:883-887.
100. Wright GL Jr, Huang CL, Lipford G, Beckett ML, Liang HM, Haley C, Newhall K, Morningstar M: Generation and characterization of monoclonal antibodies to prostate secretory protein. Int J Cancer 1990;46:39-49.
101. Mundle SD, Sheth NA: Suppression of DNA synthesis and induction of apoptosis in rat prostate by human seminal plasma inhibin (HSPI). Cell Biol Int 1993;17:587-594.
102. Lokeshwar BL, Hurkadli KS, Sheth AR, Block NL: Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res 1993;53:4855-4859.
103. Xuan, JW, Chin JL, Guo Y, Chambers AF, Finkelman MA, Clarke MW: Alternative splicing of PSP94 (prostatic secretory protein of 94 amino acids) mRNA in prostate tissue. Oncogene 1995;11:1041-1047.
104. Phillips SMA, Barton CM, Lee SJ, Morton G, Wallace DMA, Lemoine NR, Neiptolemos JP: Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994;70:1252-1257.
105. Edwards JJ, Anderson NG, Tollaksen SL, Von Eschenbach AC, Guevara J Jr: Proteins of human urine: II. Identification by two dimensional electrophoresis of a new candidate marker for prostatic cancer. Clin Chem 1982;28:160-163.
106. Kim YD, Robinson DY, Manderino GL, Tribby IIE, Tomita JT: Monoclonal antibody PR92 with restricted specificity for tumor-associated antigen of prostate and breast carcinoma. Cancer Res 1988;48:4543-4548.
107. Kim YD, Robinson DY, Manderino GL, Tribby HE, Tomita JT: Molecular characteristics of the epitope in prostate and breast tumor-associated PR92 antigen. Cancer Res 1989;49:2379-2382.
108. Carlin BI, Marachie J, Venegas MF, Schaeffer AJ, Shaw N, Mass M, Rademaker AW, Lee C, Grayhack JT: PR92 antigen in human prostate fluid elevated levels in prostate-cancer. Prostate 1994;25:156-161.
109. Wright GL Jr, Beckett ML, Lipford GB, Haley CL, Schellhammer PF: A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by momoclonal antibody TURP-27. Int J Cancer 1991;47:1717-1725.
110. Beckett ML, Lipford GB, Haley CL, Schellhammer PF, Wright GL Jr: Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. Cancer Res 1991;51:1326-1333.
111. Shen R, Su Z-Z, Olsson CA, Fisher PB: Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc Natl Acad Sci USA 1995;92:6778-6782.
112. Kamada M, Liang Z, Koide SS: Identification of IgG and Fc-binding proteins in human seminal plasma and sperm. Arch Androl 1991;27:1-7.
113. Liang ZG, Kamada M, Mitsudo SM, Doide SS: Immunoglobulin binding factor of seminal plasma: A secretory product of human prostate. Arch Androl 1992;28:159-164.
114. Maeda N, Kamada M, Daitoh T, Maegawa M, Hirano K, Aono T, Shiotsu T, Kanayama H, Kagawa S, Futaki S, Mauraguchi M, Ohmoto Y, Liang ZG, Koide SS: Immunoglobulin binding factor: A new tumor marker for prostatic tumors. Prostate 1994; 24:125-130.
115. Foti AG, Cooper JR, Hemhmann H, Mefvacz RR: Detection of prostatic cancer by solid phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med 1977;297:1357-1361.
116. Bruce AW, Mahan DE: Acid phosphatase: Its estimation and clinical significance. In Blandy JP, Lytton B (eds): "The Prostate" (BIMR Urology). Surrey: Butterworth, 1986:147-162.
117. Sakai H, Yasuo Y, Minami Y, Yushita Y, Kanetake H, Saito Y: Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advance prostatic canrcinoma. J Urol 1993;149:1020-1023.
118. Chatal IP, Daver A, Firury-Govern MC: The value of prostatic acid phosphatase (PAP) in predicting lymph node metastases in patients undergoing pelvic lymphadenectomy for prostatic cancer. (Abs. 235). Proceedings of the American Urology Association Annual Meeting, Kansas City, Missouri, 1982.
119. Oesterling JE, Brendler BC, Epstein JI, Kimball AW Jr, Walsh PC: Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 1987;138:92-97.
120. Wilson JWL, Morales A, Brtice AW: The prognostic significance of histological grading and pathological staging in carcinoma of the prostate. J Urol 1983;130:481-483.
121. Stamey TA, Kabalin JN: Proistate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989;141:1070-1075.
122. Burnett AL, Chan DW, Brendler CB, Walsh PC: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol 1992;148:1832-1834.
123. Kleer E, Larson-Keller J, Zincke H, Oesterling J: Ability of preoperative serum prostate specific antigen value to rredict pathologic stage and DNA ploidy: Influences of clinical stage and tumor grade. Urology 1993;41:207-216.
124. Kabalin JN, McNeal JE, Johnstone IM, Stamey TA: Serum prostate specific antigen and the biologic progression of prostate cancer. Urology 1995;46:65-70.
125. Kleer E, Oesterling J: PSA and staging of localized prostate cancer. Urol Clin North Am 20:695-703, 1993.
126. Partin A, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JF, Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
127. Blackledge GRP, Lowery K: Role of prostate-specific antigen as a predictor of outcome in prostate cancer. Prostate 1994;5:34-38.
128. Abdul M, Hsieh JT, Logothitis CJ, Hoosein MM: Secretion of prostate-specific antigen-supressing activity by two human prostate carcinoma cell lines. Urol Oncol 1995;1:38-41.
129. Katz A, Olsson C, Raffo A, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994;43:765-775.
130. Moreno JG, Croce CM, Rischer R, Monne M, Vihko P, Mulholland SG, Gomella LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992;52:6110-6112.
131. Seiden MV, Kantoff PW, Krithivas K Propert K, Bryant M, Haltom, E, Gaynes L, Kaplan I, Bubley G, Dewolf W, Sklar J: Detection of circulating tumor-cells in men with localized prostate-cancer. J Clin Oncol 1994;12:2634-2639.
132. Deguchi T, Doi T, Ehara H, Ito S-i, Takahashi Y, Nishino Y, Fujihiro S, Kawamura T, Komeda H, Horie M, Kaji H, Shimokawa K, Tanaka T, Kawada Y: Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcritpate polymerase chain reaction. Cancer Res 1993;53:5350-5354.
133. Murphy GP, Tino WT, Holmes EH, Boynton AL, Erickson SJ, Bowes VA, Barren RJ, Tjoa BA, Misrock SL, Ragde H, Denny GM: Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate 1996;28:266-271.
134. Gao X, Honn KV: 12-Lipoxygenase and 12(S)-HETE in cancer invasion and metastasis. Adv Oncol 1995;11(2):3-8.
135. Gao X, Honn KV: 12-Lipoxygenase as a prostate cancer marker and therapeutic target. Adv Oncol 1995;11(3):2-8.
136. Liu B, Maher RJ, Hannun YA, Porter AT, Honn KV: 12(S)-HETE enhancement of prostate tumor cell invasion: Selective role of PKCa. J Natl Cancer Inst 1994;86:1145-1151.
137. Tang DG, Honn KV: 12-Lipoxygenase, 12(S)-HETE, and cancer metastasis. Ann New York Acad Sci 1994;744:199-215.
138. Gao X, Grignon D, Chbihi T, Zacharek A, Chen YQ, Sakr W, Porter AT, Crissman JD, Pontes JE, Powell IJ, Honn KV: Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 1995;46:227-237.
139. Isaacs WB, Carter BS, Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51:4716-4720.
140. Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL: Muatnt p53 expression in prostate carcinoma. Prostate 1993;22:23-30.
141. Chi S-G, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH: p53 in prostate cancer: Frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-933.
142. Chen YQ, Gao X, Grignon D, Sarkr FH, Sakr W, Honn KV, Borders JS, Crissman JD: Multiple mechanisms of p53 inactivation in human prostate cancer. Cancer Mol Biol 1994;1:357-367.
143. Watanabe M, Ushijima T, Kakiuchin H, Shiraishi T, Yatani R, Shimazaki J, Dotake T, Sugimrua T, Nagao M: p53 gene mutations in human prostate cancers in Japan: Different mutation spectra between Japan and western countries. Jap J Cancer Res 1994;85:904-910.
144. Zhau HE, Zhao LS, Chung LWK, Chen BQ, Troncoso P, Kao C, Kojima M, Symmans WF, Zheng N, Palmer JL, Moul JW, Davis R, Ye MF, Xiao L-S, Hall MC: Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: Characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. Urol Oncol 1995;1:51-63.
145. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced stage prostate cancers. Cancer Res 1993;53:3369-3373.
146. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
147. Effert PJ, Neubauer A, Walther PJ, Liu ET: Alteration of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol 1992;147:789-793.
148. Effert PJ, McCoy RH, Walther PJ, Lui ET: p53 gene alterations in human prostate carcinoma. J Urol 1993;150:257-261.
149. Massenkeil G, Oberhuber H, Hailemariam S, Sulser T, Diener PA, Bannwart O, Schafer R, Schwartewaldhoff I: p53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate-cancer. Anticancer Res 1995;14:2785-2790.
150. Konishi N, Hiasa Y, Hayashi I, Matsuda H, Tsuzuki T, Ming T, Kitahoriu Y, Shiraishi T, Yatani R, Shimazaki J: p53 mutations occur Ln clinical, but not latent, human prostate carcinoma. Jpn J Cancer Res 1995;86:57-63.
151. Meyers FJ, Chi S-G, Fishman JR, deVere White RW, Gumerlock PH: p53 mutations in benign prostatic hyperplasia. J Natl Cancer Inst 1993;85:1856-1858.
152. Chi S-G, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH: p53 in prostate cancer: Frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-933.
153. Kubota Y, Shuin T, Uemura H, Fujianami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, Danenberg PV: Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995;27:18-24.
154. Fishel R, Kay-Lescoe M, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-1038.
155. Leach FS, Nicolaides NC, Paradopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Altonen LA, Nystrom-Lahti M, Guan XY, Zhang J, Meltzer PS, Yu JW, Kao FT, Chen DJ, Cerosaletti KM, Fournier REK, Todd S, Lewis T, Leach RJ, Naylor SL, Weissenbach J, Mecklin JP, Jarvinen H, Petersen GM, Hamilton SR, Green J, Jass J, Watson P, Lynch HT, Trent JM, de la Chapelle A, Kinzler KW, Vogelstein B: Mutations of a MutS homolog in hereditary nonpolyposis colorectal-cancer. Cell 1993;75:1215-1225.
156. Nicolaides NC, Papadopoulos N, Liu B, Wei Y-F, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser, CM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Petersen GM, de la Chapelle A, Vogelstein B, Kinzler KW: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371:75-80.
157. Uchida T, Wada C, Wang C, Ishida H, Egawa S, Yokiyama E, Ohtani H, Koshiba E: Microsatellite instability in prostate cancer. Oncogene 1995;10:1019-1022.
158. Shurbaji MS, Kuhajda FP, Pasternack GR, Thurmond TS: Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicatior. Am J Pathol 1992;97:686-691.
159. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR: Fatty acid synthesis: A potential selective target for antineioplastic therapy. Proc Natl Acad Sci USA 1994;91:6379-6383.
160. Epstein JI, Carmichael M, Partin AW: OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology 1995;45:81-86.
161. Cher ML, Chew K, Rosenau W, Carroll PR: Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995; 26:87-93.
162. Harper ME, Goddard L, Wilson DW, Matanhelia SS, Conn IG, Pelling WB, Griffiths K: Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 1992;21:75-84.
163. Carroll PR, Waldman FM, Rosenau W, Cohen MB, Vapnek JM, Fong P, Narayan P, Mayall BH: Cell proliferation in prostatic adenocarcinoma: In vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. J Urol 1993;149:403-407.
164. Harper ME, Glynne-Jones E, Goddard L, Wilson DW, Natenhelia SS, Conn IG, Pelling WB, Griffiths K: Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical paramentes. Prostate 1992;20:243-253.
165. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-1455.
166. Behrens, J: The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat 1993;24:175-184.
167. Oda T, Kanai Y, Oyama T, Yoshiura K, Shimoyama Y, Birchmeirer W, Sugimura T, Hirohashi S: E-cadherin gene mutation in human gastric carcinoma cell lines. Proc Natl Acad Sci USA 1994;91:1858-1862.
168. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M, Mori T: Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-1701.
169. Giroldi LA, Schalken JA: Decreased expression of the intracellular
170. Phillips SMA, Barton CM, Lee SJ, Morton DG, Wallace DMA, Lemoine NR, Neoptolemos JP: Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic-cancer cells. Br J Cancer 1994;70:1252-1257.
171. Bussemakers MJG, van Moorselaar RJA, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FMJ, Schalken JA: Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52:2916-2922.
172. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE, Debruyne FMJ, Isaacs WB: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high grade prostate cancer. Cancer Res 1992;52:5104-5109.
173. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMJ, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933.
174. Varki A: Biological roles of oligosaccharide: All of the theories are correct. Glycobiology 1993;3:97-130.
175. x antigens. Semin Cancer Biol 1993; 4:319-324.
176. Varki A: Selectin ligands. Proc Natl Acad Sci USA 1994;91: 7390-7397.
177. x: A new prognostic parameter in metastatic prostate cancer. Cancer Res 1995;55:1817-1819.
178. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
179. Disant' Agnese PA: Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287-296.
180. Kadmon D, Thompson TC, Lynch GR, Scardino PT: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;358-361.
181. Cohen RJ, Gelzerson G, Haffejee Z, Afrika D: Prostatic carcinoma: Histological and immunohistological features affecting prognosis. Br J Urol 1990;66:405-410.
182. Brozna JP: Cellular regulation of tissue factor. Blood Coagul Fibrinol 1990;1:415-426.
183. Adamson AS, Francis JL, Witherow, RO, Snell ME: Urinary tissue factor levels in prostatic carcinoma: A potential marker of metastatic spread? Br J Urol 1993;71:587-592.
184. Adamson AS, Luckert P, Pollard M, Snell ME, Amirkhosravi M, Francis JL: Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. Br J Cancer 1994;69:286-290.
185. Arai Y, Takeuchi H, Oishi K, Yoshida O: Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 1992;20:169-177.
186. Risteli J, Elonaa I, Niemi S, Novamo A, Risteli L: Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993;39:635-640.
187. Kylmala T, Tammela TLJ, Risteli L, Risteli J, Kontturi M, Elomaa I: Type-I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995;71:1061-1064.
188. Miyamoto KK. McSherry SA. Robins SP. Besterman JM. Mohler JL: Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 1994;151:909-913.
189. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with seum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-233.
190. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG: Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-1035.
191. Meijer L, Ostvold AC, Wallaas SI, Lund T, Laland G: High-mobility group proteins P1 and Y as substrates of the M-phase specific p34cdc2/cyclin cdc13 kinase. Eur J Biochem 1991;196: 557-567.
192. Bussemakers MJG, Van de Ven WJM, Debruyne FMJ, Schalken JA: Identification of high mobility group protein I(Y) as potential marker of prostate cancer by differential hybridization analysis. Cancer Res 1991;51:606-611.
193. Tamimi Y, van der Poel HG, Denyn M-M, Umbas R, Karthau HFM, Debruyne FMJ, and Schalken JA: Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res 1993;53:5512-5516.
194. Liotta LA, Sheeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327-336.
195. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J: Serum metalloproteinases and their inhibitors: Markers for malignant potential. Br J Cancer 1994;70:506-512.